You may have questions before starting treatment with HUMIRA, or as your treatment progresses. Our goal is to provide information and support—both now, and as you continue using HUMIRA to help control your non-infectious uveitis.*
Keep in mind, everyone responds differently to treatment. However, in one clinical study of adult patients with active, non-infectious intermediate, posterior, and panuveitis taking HUMIRA, participants saw a difference in disease control as early as week 6. Individual results may vary. Talk to your doctor to see if HUMIRA is right for you.
Important: You must pay attention to your starting dose—it may be different than your maintenance dose and is a critical part of taking HUMIRA as prescribed. Make sure you have been shown how to inject HUMIRA before you do it yourself. Your first injection must be given under the supervision of a health care professional. Remember to keep your HUMIRA refrigerated in its original container until ready for use.
The starting dose of HUMIRA for adult patients with non-infectious uveitis is 80 mg (milligrams) on Day 1 (2 Pens). The maintenance dose is 40 mg on Day 8 (1 Pen), and 40 mg every other week thereafter. Always follow your doctor's instructions about when and how often to take HUMIRA. If you need additional help with self-injecting, you can view an instructional video here.
For more information, refer to the Patient Instructions for Use, and the Medication Guide located inside your HUMIRA carton, and within the Full Prescribing Information.
Starting dose
On Day 1 only
You will inject 2 HUMIRA 40 mg/0.8 mL Pens
(80 mg)
Maintenance dose
On Day 8 and every other week thereafter
You will inject 1 HUMIRA Pen
(40 mg/0.8 mL)
If your child weighs at least 22 lbs and under 33 lbs
Recommended dose every other week
10 mg
10 mg/0.1 mL prefilled syringe
If your child weighs at least 33 lbs and less than 66 lbs
Recommended dose every other week
20 mg
20 mg/0.2 mL prefilled syringe
If your child weighs 66 lbs or more
Recommended dose every other week
40 mg
40 mg/0.4 mL HUMIRA Pen or prefilled syringe
Remember, HUMIRA is a treatment, not a cure. Your doctor can tell you if and when you should stop taking HUMIRA.
If you experience any adverse reactions or discomfort when taking HUMIRA, discuss them with your doctor right away.
Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
*HUMIRA (adalimumab) is approved for the treatment of non-infectious intermediate, posterior, and panuveitis in adults and and children 2 years of age and older.
US-HUM-190411
